Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
enliGHten long-term TransCon hGH in pediatric growth hormone deficiency
2017-003410-20Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Jan 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lonapegsomatropin in growth hormone deficiency (GHD), sponsored by Ascendis Pharma. Primary endpoint: Long-term safety of weekly TransCon hGH. Started Jan 2018; status: completed.
02
Drugs
lonapegsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2017-003410-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003410-20.